SAN DIEGO, April 15, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced it has been awarded a research contract by Lawrence Livermore National Laboratory (LLNL), part of the U.S. Department of Energy's National Nuclear Security Administration, for the development of novel antibiotics directed against multi-drug resistant (MDR) bacterial pathogens. Trius may receive up to $3.0 million over three years in support of its development efforts. This award brings the Company's total federal contract awards to $60 million over the last three years.
